secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001493152-23-027107
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics Q2 net loss $16.7M; on track for EB-101 BLA submission in Q3 2023
--------------------------------------------------------------------------------

- Net loss $16.7M ($0.92/share) vs $7.9M ($1.36/share) in Q2 2022; revenue $3.5M from license.
- Cash $37.1M at June 30; $25M July offering extends runway into Q4 2024.
- BLA submission for EB-101 in RDEB on track for Q3 2023; pre-BLA briefing submitted to FDA.
- Completed Process Performance Qualification runs for commercial production of EB-101.
- Additional Phase 3 VIITAL efficacy/safety data presented at ISID and SPD meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/0001493152-23-027107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer